PI3K pathway inhibition in GBM - Is there a signal?

Neuro-Oncology

Volumn 17, Issue 9, 2015, Pages 1183-1184

  Nichol, Donna ^a   Mellinghoff, Ingo K ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; SONOLISIB; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; GONANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BRAIN BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; DRUG TUMOR LEVEL; EDITORIAL; ENZYME INHIBITION; FOLLOW UP; GENE MUTATION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PIK3R1 GENE; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PTEN GENE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; FEMALE; MALE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; EVEROLIMUS; FEMALE; GLIOBLASTOMA; GONANES; HUMANS; MALE;

EID: 84940761007     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov124     Document Type: Editorial

References (17)

1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-1812.
2. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
3. Rodon J, Dienstmann R, Serra V, et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143-153.
4. Ma DJ, Galanis E, Anderson SK, et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol. 2014; [Epub ahead of print].
5. Eshleman JS, Carlson BL, Mladek AC, et al. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 2002;62(24):7291-7297.
6. Pitz MW, Eisenhauer EA, MacNeil MV, et al. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol. 2015;17(9): 1270-1274.
7. Ihle NT, Lemos R Jr, Wipf P, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009;69(1): 143-150.
8. Koul D, Shen R, Kim YW, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010;12(6):559-569.
9. Waldherr C, Mellinghoff IK, Tran C, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med. 2005;46(1):114-120.
10. Li Z, Herrmann K, Pirsig S, et al. Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma. Am J Nucl Med Mol Imaging. 2013;4(1):70-79.
11. Cawthorne C, Burrows N, Gieling RG, et al. [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941. Mol Cancer Ther. 2013;12(5):819-828.
12. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5(1):e8.
13. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005; 23(23):5294-5304.
14. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7-24.
15. Elkabets M, Vora S, Juric D, et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med. 2013;5(196):196ra99.
16. Corcoran RB, Rothenberg SM, Hata AN, et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013;5(196):196ra98.
17. Klempner SJ, Myers AP, Cantley LC. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov. 2013;3(12): 1345-1354.